|Videos|January 30, 2015
Final Thoughts on Improving Outcomes in CRC
Advertisement
Episodes in this series
In the final segment of the discussion, the expert panel shares their thoughts on the current state of treatment for patients with metastatic colorectal cancer (mCRC).
Dan Haller, MD, explains that overall survival for mCRC has improved 5-fold since he trained as a fellow, back when there was only fluorouracil; in fact, some patients with metastatic disease are now being cured. It’s important to realize how far we’ve come, he comments.
Axel Grothey, MD, says there is no clear winner when it comes to choosing first-line therapy for mCRC. There are several options, and it’s not a one-size-fits-all scenario. The next generation of big questions will be answered by diving into the subset analyses of large phase III studies, he suggests.
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5